In the current study, we report that gBRCA1 carriers but not gBRCA2 carriers are at high risk of developing grade 3–4 neutropenia and are more likely to need secondary prophylaxis with G-CSF to complete their neoadjuvant or adjuvant chemotherapy. The gene discussed is CSF3; the disease is neutropenia.